Alpine Immune Sciences Inc buy melinda
Summary
This prediction ended on 06.03.17 with a price of €9.53. The BUY prediction by melinda finished with a performance of 12.27%. melinda has 50% into this predictionAlpine Immune Sciences is a clinical-stage biotechnology company focused on developing novel therapies that modulate the immune system to treat cancer, autoimmune, and inflammatory diseases. The company's proprietary platform technology, called "Variant Ig Domain" (vIgD), enables the design and development of unique protein therapeutics that can target specific immune cells and pathways. Alpine's lead product candidate, ALPN-202, is a dual ICOS/CD28 antagonist for the treatment of autoimmune and inflammatory diseases, and the company has several other product candidates in preclinical development. Alpine Immune Sciences is listed on the NASDAQ stock exchange under the ticker symbol "ALPN".
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alpine Immune Sciences Inc | - | - | - | - |
iShares Core DAX® | 1.164% | 1.549% | 24.351% | 23.659% |
iShares Nasdaq 100 | 0.118% | 0.969% | 28.865% | 41.786% |
iShares Nikkei 225® | 1.124% | -1.120% | 17.443% | 6.454% |
iShares S&P 500 | 0.479% | 1.068% | 28.585% | 42.511% |
Comments by melinda for this prediction
In the thread Alpine Immune Sciences Inc diskutieren
folgen
Nivalis Therapeutics, ein pharmazeutisches Unternehmen im klinischen Stadium, entdeckt, entwickelt und vermarktet Produkte Kandidaten für Patienten mit zystischer Fibrose -
Stopped prediction by melinda for Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
29.02.20
04.11.21
05.11.21
Alpine Immune Sciences Inc
13.10.18
22.01.19
22.01.19